Skip to main content
. 2018 Sep-Oct;22(5):689–695. doi: 10.4103/ijem.IJEM_104_18

Table 2.

Baseline characteristic of study population in CV safety studies of DPP-4 inhibitors[21,22,23,40,47]

graphic file with name IJEM-22-689-g003.jpg